查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1995452

荷尔蒙避孕药市场：按类型、荷尔蒙成分、销售管道和最终用户划分－2026-2032年全球市场预测

Hormonal Contraceptives Market by Contraceptive Type, Hormonal Composition, Sales Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，荷尔蒙避孕药市场价值将达到 186.5 亿美元，到 2026 年将成长至 201.7 亿美元，到 2032 年将达到 341.4 亿美元，复合年增长率为 9.01%。

主要市场统计数据
基准年 2025 186.5亿美元
预计年份：2026年 201.7亿美元
预测年份 2032 341.4亿美元
复合年增长率 (%) 9.01%

将影响荷尔蒙避孕药市场的临床、监管和主导因素置于具体情境中，以指导经营团队决策和策略重点。

本报告引言概述了荷尔蒙避孕药的现状，从为高级相关人员量身定制的综合观点出发，分析了临床创新、使用者偏好、监管趋势和供应链复杂性。长效可逆避孕药的进步，以及对避孕选择和可及性的重新重视，重塑了临床路径和采购重点。同时，报销政策的转变和监管指南的不断完善，也正在改变现有产品和新产品的核准时间和商业化路径。

配方、管理系统、数位化照护路径和以公平为中心的政策转变方面的进步，正在全面重塑避孕药具的提供和分发趋势。

荷尔蒙避孕领域的变化是製剂、给药方式和服务模式创新融合的结果，它正在改变人们获取和获得避孕服务的方式。随着医疗服务提供者寻求减轻使用者负担并提高用药依从性，长效避孕药正日益普及。同时，新一代製剂和新型给药平台正努力平衡疗效和耐受性。除了产品创新之外，医疗路径的数位化和远端医疗在处方开立方面的应用也正在拓展服务管道，重塑患者体验，并改变传统药房和诊所在启动治疗和后续观察的作用。

本研究评估了美国2025年关税政策的转变将如何促进供应链多元化、区域生产投资和采购结构的调整。

美国2025年实施的关税对避孕药具供应链、采购惯例和商业重点产生了多方面的影响。关税带来的成本压力迫使製造商和经销商重新评估筹资策略，加快推进特定生产流程的本地化、供应商多元化以及重新谈判供应商合同，以在不影响产品品质的前提下维持利润率。因此，一些公司优先投资区域生产能力，并与供应商建立双边关係，以降低贸易政策变化带来的风险。

将避孕药类型、荷尔蒙成分、分销管道和最终用户环境联繫起来的详细细分观点，为优先排序和商业化提供了指南。

市场区隔洞察揭示了产品属性、荷尔蒙成分、分销管道和终端用户环境之间的交集，以及这些因素如何影响避孕产品的采纳和方案设计。根据避孕方式的不同，市场包括植入、注射避孕药、子宫内避孕器 (IUD)、口服避孕药、经皮吸收贴片和阴道环。植入方面，双桿和单桿设计导致不同的植入流程和对医护人员的训练要求。注射避孕药则分为长效型Medroxyprogesterone製剂和庚酸型炔诺酮製剂，二者在给药间隔和给药环境方面有差异。口服避孕药分为复方口服避孕药和黄体素单药製剂，二者在处方注意事项上有所不同。阴道环分为长期使用型和月用型，二者对用药依从性和咨询的影响也不同。

检验了美洲、欧洲、中东和非洲以及亚太地区的监管多样性、采购模式以及数位技术的采用如何塑造差异化的战略应对措施。

区域趋势反映了不同的需求驱动因素、法律规范和分销挑战，从而塑造了各区域的战略重点。在美洲，支付方结构、公共卫生计画和私人医疗服务提供者网路相互作用，影响部署模式和采购模式，尤其需要关註生殖健康政策的变化如何影响医疗服务的可近性和资金流动。欧洲、中东和非洲的监管环境呈现异质性，在这些地区，监管协调的努力与不同的报销环境和基础设施限制并存，这些因素影响产品选择和部署策略。在亚太地区，快速的都市化、数位医疗的普及和不断扩大的製造能力，在为企业应对不同的监管预期和当地市场准入要求时，既创造了商业性机会，也带来了营运上的复杂性。

产品差异化、伙伴关係策略和营运韧性如何决定老牌公司与新兴避孕创新者之间的竞争。

竞争考察重点阐述了老牌製药公司和新兴专业公司在产品创新、供应链韧性和市场策略等领域的应对策略。主要企业正投资于改进配方和差异化给药机制，以解决耐受性和依从性问题；而新参与企业和细分市场企业则专注于长效阴道环和新一代皮下植入式装置等专业平台。伙伴关係与授权协议正成为加快产品上市速度、拓展产品系列且无需承担全部研发成本的战术性策略。

产业领导者应采取的切实可行的策略重点和营运措施，以使产品开发、分销和相关人员参与与不断发展的医疗保健模式保持一致。

针对行业领导者的实际建议着重于使产品开发、商业性执行和营运系统与不断变化的用户和政策实际情况相适应。首先，应优先考虑能够减轻使用者负担并提高用药依从性的开发路径，例如长效製剂和便捷的给药系统，同时确保临床和安全性指标能够满足患者的多样化需求。其次，应透过供应商多元化、区域化生产以及确保价格和销售在政策波动下保持稳定的合约机制，来增强供应链的韧性。

为了确保分析的严谨性，我们采用了一种透明的混合方法研究途径，结合了对主要相关人员的访谈、对监管和临床证据的审查以及专家检验。

本调查方法采用混合方法，确保研究在临床、监管和商业领域均具有深度和相关性。主要调查包括对临床医生、采购负责人和保险公司进行结构化访谈，以获取关于处方行为、采购限制和准入障碍的第一手观点。次要调查包括对监管指南、临床文献和公共声明进行全面审查，以验证和补充主要调查的结果。

本文概述了将临床创新、分销演变和供应韧性联繫起来的策略挑战，以促进荷尔蒙避孕药的获取和分销。

总之，荷尔蒙避孕药正处于影响其取得和分销的临床创新、不断演变的医疗服务模式以及政策趋势的交汇点。长效和以使用者为中心的给药方式正日益普及，而数位化管道和医疗专业人员教育正在改变传统的分销和咨询模式。同时，贸易政策的变化和供应链压力凸显了製定具有韧性的筹资策略和提升区域营运能力的重要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：以避孕方法分類的荷尔蒙避孕药市场

  • 植入
    • 双叉植入
    • 单桿植入
  • 注射式避孕药
    • 长效型Medroxyprogesterone
    • 去甲睾酮庚酸酯
  • 避孕器
  • 口服避孕药
    • 复方口服避孕药
    • 仅含黄体素的避孕药
  • 经皮贴剂
  • 阴道环
    • 长期使用戒指
    • 月环

第九章：依荷尔蒙成分分類的荷尔蒙避孕药市场

  • 荷尔蒙避孕药
  • 仅含黄体素的避孕药

第十章：荷尔蒙避孕药市场：依销售管道划分

  • 医院药房
  • 网路药房
  • 零售药房

第十一章：荷尔蒙避孕药市场：以最终用户划分

  • 诊所
    • 私人诊所
    • 公立诊所
  • 家庭医疗保健
  • 医院

第十二章：荷尔蒙避孕药市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：荷尔蒙避孕药市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：荷尔蒙避孕药市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国荷尔蒙避孕药市场

第十六章：中国荷尔蒙避孕药市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Allergan plc
  • Bayer AG
  • Cipla Limited
  • Gedeon Richter plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-4103B31E0668

The Hormonal Contraceptives Market was valued at USD 18.65 billion in 2025 and is projected to grow to USD 20.17 billion in 2026, with a CAGR of 9.01%, reaching USD 34.14 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 18.65 billion
Estimated Year [2026] USD 20.17 billion
Forecast Year [2032] USD 34.14 billion
CAGR (%) 9.01%

Contextualizing clinical, regulatory, and access-driven forces shaping the hormonal contraceptives landscape to guide executive decision-making and strategic priorities

The introduction frames the current hormonal contraceptives landscape by situating clinical innovation, user preferences, regulatory dynamics, and supply chain complexity within an integrated perspective tailored for senior stakeholders. Advances in long-acting reversible contraceptives alongside renewed emphasis on contraceptive choice and access have reshaped clinical pathways and procurement priorities. At the same time, shifting reimbursement policies and evolving guidance from regulatory authorities have altered approval timelines and commercial pathways for both incremental and novel products.

Consequently, leaders must consider not only product attributes but also the broader ecosystem that governs adoption, including provider education, digital channels for user engagement, and distribution resilience. This summary synthesizes cross-functional signals to clarify where clinical efficacy, patient-centered design, and operational readiness intersect. By aligning strategic priorities with these systemic trends, organizations can better anticipate adoption hurdles, optimize commercialization sequencing, and strengthen stakeholder partnerships that underpin sustainable growth in contraceptive provision.

How advancements in formulations, delivery systems, digital care pathways, and equity-driven policy shifts are collectively reshaping contraceptive provision and adoption trends

Transformative shifts in the hormonal contraceptives landscape reflect converging innovations in formulation, delivery, and service models that are changing how contraceptive care is accessed and delivered. Long-acting methods have gained traction as providers seek to reduce user burden and increase adherence, while next-generation formulations and novel delivery platforms seek to balance efficacy with tolerability. Parallel to product innovation, digitization of care pathways and telehealth-enabled prescribing have expanded points of access, reshaping patient journeys and altering the role that traditional pharmacy and clinic channels play in initiation and follow-up.

In addition, heightened attention to reproductive autonomy and equity has prompted policy shifts and funding reallocations that influence procurement and public health programming. Supply chain resilience has become a competitive differentiator, as manufacturers and distributors respond to geopolitical pressures and raw material constraints with inventory strategies and diversified sourcing. Taken together, these dynamics are producing a more user-centric, technology-enabled, and supply-conscious environment that requires nimble commercialization models and closer collaboration across clinical, regulatory, and commercial functions.

Assessing how 2025 tariff policy shifts in the United States catalyzed sourcing diversification, regional production investments, and procurement adaptations across supply chains

The introduction of tariffs in the United States in 2025 has had a multi-dimensional influence on the contraceptive supply chain, procurement practices, and commercial prioritization. Tariff-driven cost pressures have prompted manufacturers and distributors to reassess sourcing strategies, accelerating efforts to localize certain manufacturing steps, diversify supplier bases, and renegotiate supplier contracts to preserve margins without compromising product quality. As a result, some firms have prioritized investments in regional production capacity and bi-lateral supplier relationships to mitigate exposure to trade policy volatility.

Moreover, procurement entities and institutional buyers have adapted by revising purchasing cycles and inventory buffers to manage pricing uncertainty. This has impacted negotiation dynamics between suppliers and large purchasers, with increased emphasis on total cost of ownership, contracted price stability, and supply guarantees. Regulatory teams have also observed administrative effects as cost adjustments ripple through reimbursement discussions and tenders. While tariffs are one factor among many shaping commercial choices, they have acted as a catalyst for operational resilience strategies and accelerated localization considerations that will influence sourcing roadmaps and supplier selection for the foreseeable future.

Detailed segmentation-driven perspectives linking contraceptive type, hormonal composition, distribution channels, and end-user settings to inform prioritization and commercialization

Segmentation insights reveal where product attributes, hormonal composition, distribution channels, and end-user settings intersect to shape adoption and program design. Based on contraceptive type, the landscape includes implants, injectable contraceptives, intrauterine devices, oral contraceptives, transdermal patches, and vaginal rings; within implants, distinctions between double-rod and single-rod designs drive different insertion workflows and provider training needs, while injectable contraceptives divide into depot medroxyprogesterone acetate and norethisterone enanthate formulations that differ in dosing intervals and administration settings. Oral contraceptives bifurcate into combined oral contraceptives and progestin-only pills with distinct prescribing considerations, and vaginal rings are differentiated by extended-use and monthly ring options that carry divergent adherence and counseling implications.

Based on hormonal composition, the field separates into combined hormonal contraceptives and progestin-only contraceptives, a partition that matters clinically for contraindications, side-effect profiles, and patient selection. When viewed through the lens of sales channel, hospital pharmacies, online pharmacies, and retail pharmacies each present unique distribution economics, compliance requirements, and opportunities for digital engagement. Finally, based on end user, clinics, home healthcare, and hospitals represent varied points of care; clinics themselves divide into private and public clinics, creating distinct procurement pathways and payer interactions. Together, these segment dimensions inform product development priorities, clinical training investments, and channel strategies that align with both user preferences and provider workflows.

Examining how regional regulatory diversity, procurement models, and digital adoption across the Americas, Europe Middle East & Africa, and Asia-Pacific shape differentiated strategic responses

Regional dynamics demonstrate differentiated demand drivers, regulatory frameworks, and distribution challenges that shape strategic priorities across geographies. In the Americas, payer structures, public health programs, and private provider networks interact to influence uptake patterns and procurement models, with particular attention to reproductive health policy shifts that affect access and funding flows. The Europe, Middle East & Africa region presents a heterogeneous regulatory mosaic, where regulatory harmonization efforts coexist with varied reimbursement landscapes and infrastructure constraints that influence product selection and implementation strategies. In Asia-Pacific, rapid urbanization, digital health adoption, and manufacturing capacity expansion have created both commercial opportunities and operational complexities, as firms navigate diverse regulatory expectations and local market entry requirements.

Consequently, regional strategies must balance global product platforms with tailored approaches to distribution, pricing, and provider engagement. Cross-border logistics considerations and regional manufacturing investments have become increasingly relevant to maintain continuity of supply and competitive positioning. By mapping clinical, regulatory, and commercial levers region by region, organizations can prioritize investments that align with local access priorities while leveraging scale where regulatory convergence or manufacturing synergies exist.

How product differentiation, partnership strategies, and operational resilience define competitive positioning among established and emerging contraceptive innovators

Competitive insights highlight how established pharmaceutical firms and emerging specialists are responding across product innovation, supply chain resilience, and go-to-market strategies. Leading companies are investing in formulation improvements and differentiated delivery mechanisms to address tolerability and adherence, while newer entrants and niche players focus on specialized platforms such as extended-duration rings or next-generation subdermal devices. Partnerships and licensing arrangements have become tactical levers to accelerate time-to-clinic and broaden product portfolios without bearing the full cost of development.

Operationally, firms are strengthening supplier diversification and pursuing regional manufacturing or contract manufacturing arrangements to reduce exposure to trade disruptions. Commercially, there is an increased emphasis on provider education, digital engagement tools, and value-based contracting to demonstrate outcomes and secure formulary placement. At the same time, privacy, pharmacovigilance, and post-market surveillance have escalated in importance, prompting investments in real-world evidence generation and patient-reported outcomes programs. Together, these initiatives reflect a competitive environment where clinical differentiation, operational robustness, and evidence-driven commercialization determine sustained advantage.

Practical strategic priorities and operational measures industry leaders should adopt to align product development, distribution, and stakeholder engagement with evolving care models

Actionable recommendations for industry leaders focus on aligning product development, commercial execution, and operational systems to emergent user and policy realities. First, prioritize development pathways that reduce user burden and improve adherence, such as longer-acting formulations and intuitive delivery systems, while ensuring that clinical and safety profiles meet diverse patient needs. Second, strengthen supply chain resilience through supplier diversification, regional manufacturing options, and contractual mechanisms that provide price and volume stability under policy shifts.

Third, invest in multi-channel distribution strategies that integrate hospital pharmacies, retail and online pharmacies, and telehealth-enabled prescribing to broaden access and streamline patient journeys. Fourth, enhance provider and payer engagement through evidence packages that emphasize real-world outcomes, cost-effectiveness, and implementation support. Finally, embed equity and access objectives into product and commercial planning to address disparities in contraceptive access. Implementing these recommendations requires coordinated governance across R&D, regulatory, supply chain, and commercial functions to translate strategic intent into measurable outcomes.

Transparent mixed-methods research approach integrating primary stakeholder interviews, regulatory and clinical evidence review, and expert validation to ensure analytical rigor

The research methodology combined a mixed-methods approach to ensure depth and validity across clinical, regulatory, and commercial domains. Primary research included structured interviews with clinicians, procurement professionals, and payers to capture firsthand perspectives on prescribing behaviors, procurement constraints, and access barriers. Secondary research entailed a comprehensive review of regulatory guidance, clinical literature, and public policy statements to triangulate primary findings and provide contextual grounding.

Data synthesis emphasized cross-validation, whereby qualitative insights informed the interpretation of regulatory and operational signals, and documentary evidence corroborated recurring themes. Expert review sessions with clinical and supply chain specialists refined assumptions and clarified technical implications. Transparency was maintained regarding sources of evidence and analytical assumptions, and known limitations-such as jurisdictional heterogeneity in regulatory rules and evolving tariff landscapes-were explicitly documented to guide interpretation and application of findings.

Summarizing strategic imperatives that connect clinical innovation, distribution evolution, and supply resilience to advance access and adoption of hormonal contraceptives

In conclusion, hormonal contraceptives are situated at the intersection of clinical innovation, evolving care delivery models, and policy dynamics that together shape access and adoption. Long-acting and user-centric delivery approaches are gaining momentum, while digital channels and provider education are altering traditional distribution and counseling models. Concurrently, trade policy shifts and supply chain pressures underscore the need for resilient sourcing strategies and regional operational capacity.

Decision-makers who align product development with provider workflows, invest in diversified distribution channels, and prioritize evidence generation for real-world outcomes will be best positioned to respond to both clinical and commercial imperatives. By integrating these strategic priorities with operational safeguards and stakeholder engagement plans, organizations can more effectively support access, drive adoption, and contribute to improved reproductive health outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hormonal Contraceptives Market, by Contraceptive Type

  • 8.1. Implants
    • 8.1.1. Double-Rod Implants
    • 8.1.2. Single-Rod Implants
  • 8.2. Injectable Contraceptives
    • 8.2.1. Depot Medroxyprogesterone Acetate
    • 8.2.2. Norethisterone Enanthate
  • 8.3. Intrauterine Devices
  • 8.4. Oral Contraceptives
    • 8.4.1. Combined Oral Contraceptives
    • 8.4.2. Progestin-Only Pills
  • 8.5. Transdermal Patches
  • 8.6. Vaginal Rings
    • 8.6.1. Extended-Use Rings
    • 8.6.2. Monthly Rings

9. Hormonal Contraceptives Market, by Hormonal Composition

  • 9.1. Combined Hormonal Contraceptives
  • 9.2. Progestin-Only Contraceptives

10. Hormonal Contraceptives Market, by Sales Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies

11. Hormonal Contraceptives Market, by End User

  • 11.1. Clinics
    • 11.1.1. Private Clinics
    • 11.1.2. Public Clinics
  • 11.2. Home Healthcare
  • 11.3. Hospitals

12. Hormonal Contraceptives Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Hormonal Contraceptives Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Hormonal Contraceptives Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Hormonal Contraceptives Market

16. China Hormonal Contraceptives Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Allergan plc
  • 17.6. Bayer AG
  • 17.7. Cipla Limited
  • 17.8. Gedeon Richter plc
  • 17.9. Johnson & Johnson
  • 17.10. Merck & Co., Inc.
  • 17.11. Pfizer Inc.
  • 17.12. Sun Pharmaceutical Industries Ltd.
  • 17.13. Teva Pharmaceutical Industries Ltd.
  • 17.14. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HORMONAL CONTRACEPTIVES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HORMONAL CONTRACEPTIVES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES HORMONAL CONTRACEPTIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA HORMONAL CONTRACEPTIVES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY DOUBLE-ROD IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY DOUBLE-ROD IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY DOUBLE-ROD IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY SINGLE-ROD IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY SINGLE-ROD IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY SINGLE-ROD IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY DEPOT MEDROXYPROGESTERONE ACETATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY DEPOT MEDROXYPROGESTERONE ACETATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY DEPOT MEDROXYPROGESTERONE ACETATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY NORETHISTERONE ENANTHATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY NORETHISTERONE ENANTHATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY NORETHISTERONE ENANTHATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY INTRAUTERINE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY INTRAUTERINE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY INTRAUTERINE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PROGESTIN-ONLY PILLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PROGESTIN-ONLY PILLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PROGESTIN-ONLY PILLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY TRANSDERMAL PATCHES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY TRANSDERMAL PATCHES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY EXTENDED-USE RINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY EXTENDED-USE RINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY EXTENDED-USE RINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY MONTHLY RINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY MONTHLY RINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY MONTHLY RINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY COMBINED HORMONAL CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY COMBINED HORMONAL CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY COMBINED HORMONAL CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PROGESTIN-ONLY CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PROGESTIN-ONLY CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PROGESTIN-ONLY CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PRIVATE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PRIVATE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PUBLIC CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PUBLIC CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PUBLIC CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 175. GCC HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GCC HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. GCC HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 178. GCC HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 179. GCC HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 180. GCC HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2032 (USD MILLION)
  • TABLE 181. GCC HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 182. GCC HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. GCC HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. GCC HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 205. G7 HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. G7 HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. G7 HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 208. G7 HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 209. G7 HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 210. G7 HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2032 (USD MILLION)
  • TABLE 211. G7 HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 212. G7 HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. G7 HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. G7 HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 215. NATO HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. NATO HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. NATO HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 218. NATO HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 219. NATO HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 220. NATO HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2032 (USD MILLION)
  • TABLE 221. NATO HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 222. NATO HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. NATO HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. NATO HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES HORMONAL CONTRACEPTIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA HORMONAL CONTRACEPTIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)